Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses

Journal of Infectious Diseases

Volumn 211, Issue 9, 2015, Pages 1408-1417

  Nayak, Jennifer L ^a   Richards, Katherine A ^b   Yang, Hongmei ^a   Treanor, John J ^a   Sant, Andrea J ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Center for Vaccine Biology and Immunology   (United States)

Author keywords

Avian influenza; CD4+ T cells; H5N1; Influenza; Influenza vaccine; Pandemic influenza

Indexed keywords

EPITOPE; HEMAGGLUTININ; INFLUENZA A/INDONESIA/5/05(H5N1) VACCINE; INFLUENZA A/THAILAND/4(SP-528)/04(H5N1); INFLUENZA A/VIETNAM/1203/2004 VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA A (H5N1); MAJOR CLINICAL STUDY; MALE; PANDEMIC; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINATION; VIRUS REACTIVATION; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; MIDDLE AGED; PANDEMICS; PHYSIOLOGY;

CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS;

EID: 84928911808     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu616     Document Type: Article

References (50)

1. Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003-2014. http://www.who.int/influenza/human-animal-interface/EN-GIP-20140124CumulativeNumberH5N1 cases.pdf?ua=1. Accessed 19 June 2014.
2. Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008; 371:1427-34.
3. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis 2007; 13:1348-53.
4. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333-40.
5. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 336:1534-41.
6. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassor-tant H5 HA/H1N1 virus in ferrets. Nature 2012; 486:420-8.
7. Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012; 336:1541-7.
8. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
9. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenic-ity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
10. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667-75.
11. Vesikari T, Forsten A, Herbinger KH, et al. Safety and immunogenicity of an MF59((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012; 30:1388-96.
12. Vesikari T, Karvonen A, Tilman S, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010; 126:e762-70.
13. Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis JP, Villari P. Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis 2009; 9:482-92.
14. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
15. Stohr K. Vaccinate before the next pandemic? Nature 2010; 465:161.
16. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol Biol 2012; 865:147-62.
17. Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-41.
18. Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011; 203:666-73.
19. Talaat KR, Luke CJ, Khurana S, et al. A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response. J Infect Dis 2014; 209:1860-9.
20. Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:1631-3.
21. Khurana S, Coyle EM, Dimitrova M, et al. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. PLoS One 2014; 9:e95496.
22. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106:7962-7.
23. Baer J, Santiago F, Yang H, et al. B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine 2010; 28:907-15.
24. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29:621-63.
25. Nutt SL, Tarlinton DM. Germinal center B and follicular helper T cells: siblings, cousins or just good friends? Nat Immunol 2011; 12:472-7.
26. Ramiscal RR, Vinuesa CG. T-cell subsets in the germinal center. Immunol Rev 2013; 252:146-55.
27. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012; 209: 1241-53.
28. Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4 T-cell expansion predicts neutralizing antibody responses to monovalent inactivated pandemic H1N1 influenza vaccine. J Infect Dis 2013; 207:297-305.
29. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106:3877-82.
30. Pedersen GK, Madhun AS, Breakwell L, et al. T-Helper 1 Cells Elicited by H5N1 Vaccination Predict Seroprotection. J Infect Dis 2012; 206:158-66.
31. Bentebibel SE, Lopez S, Obermoser G, et al. Induction of ICOS-+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013; 5:176ra32.
32. Spensieri F, Borgogni E, Zedda L, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci USA 2013; 110:14330-5.
33. Nayak JL, Alam S, Sant AJ. Cutting edge: Heterosubtypic influenza infection antagonizes elicitation of immunological reactivity to hemag-glutinin. J Immunol 2013; 191:1001-5.
34. Alam S, Knowlden ZA, Sangster MY, Sant AJ. CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J Virol 2014; 88:314-24.
35. Alam S, Sant AJ. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol 2011; 85:13310-21.
36. Richards KA, Topham D, Chaves FA, Sant AJ. Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol 2010; 185:4998-5002.
37. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
38. Sette A, Moutaftsi M, Moyron-Quiroz J, et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008; 28:847-58.
39. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev 2012; 247:52-63.
40. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol 2012; 12:24-34.
41. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 2008; 180:1758-68.
42. Jameson J, Cruz J, Terajima M, Ennis FA. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999; 162:7578-83.
43. Richards KA, Chaves FA, Sant AJ. Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. J Virol 2009; 83:6566-77.
44. Cusick MF, Wang S, Eckels DD. In vitro responsesto avian influenza H5 by human CD4 T cells. J Immunol 2009; 183:6432-41.
45. Lee LY, Ha do LA, Simmons C, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118:3478-90.
46. Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012; 7:e49704.
47. Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97.
48. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4(+) T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80.
49. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006; 103:5935-40.
50. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006; 442:448-52.